Evidence map›Paper›PMID 39025650›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study.

Siddhartha Baxi, Saima Vohra, Angela Hong, Nicola Mulholland, Martin Heuschkel, Gerhard Dahlhoff, Giuseppe Cardaci, Siroos Mirzaei, Mike Sathekge

Abstract readMulticenter StudyClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. TargetedFrontiers in medicine · 2025
    Pooled it
  2. Efficacy and Safety of Epidermal Radionuclide Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siddhartha BaxiGenesis Cancer Care, John Flynn Hospital, Tugun, Queensland, Australia.
Saima VohraAvion Medical Skin Centres, North Melbourne, Victoria, Australia.
Angela HongGenesis Cancer Care, North Shore Health Hub, St. Leonards, New South Wales, Australia.
Nicola MulhollandDepartment of Nuclear Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Martin HeuschkelDepartment of Nuclear Medicine, University Medical Center Rostock, Rostock, Germany.
Gerhard DahlhoffOncoBeta International GmbH, Munich, Germany; gerhard.dahlhoff@oncobeta.com.
Giuseppe CardaciDepartment of Nuclear Imaging, Hollywood Private Hospital, Nedlands, Western Australia, Australia.
Siroos MirzaeiClinic Ottakring, Institute of Nuclear Medicine with PET Center, Vienna, Austria; and.
Mike SathekgeDepartment of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonmelanoma skin cancer and its treatment represent a significant global cancer burden for health care systems and patients. Rhenium skin cancer therapy (Rhenium SCT) is a novel noninvasive radionuclide nonmelanoma skin cancer treatment, which can be provided in a single outpatient session. The aim of this prospective, multicenter, single-arm, international, phase IV study (EPIC-Skin) is to assess clinic- and patient-reported outcomes of Rhenium SCT as a treatment for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

Indexed as

Carcinoma, Squamous CellRheniumSkin NeoplasmsAdultAgedAged, 80 and overBasal Cell CarcinomaFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment OutcomeRheniumnonmelanoma skin cancerradionuclideRhenium SCT

Identifiers

PMID39025650
PMCPMC11372259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.